Back to top

Analyst Blog

Acura Pharmaceuticals, Inc. ((ACUR)) recently gave an update on its next generation pseudoephedrine hydrochloride tablet, Nexafed, which was launched in Dec 2012.

Nexafed (30mg) is an immediate-release, next generation pseudoephedrine tablet which combines effective nasal congestion relief with IMPEDE technology that disrupts the conversion of pseudoephedrine into the dangerous drug, methamphetamine. The drug also meets a key human clinical efficacy standard of the U.S. Food and Drug Administration (FDA).

As per the 2011 National Survey on Drug Use and Health, roughly 439,000 Americans (≥ 12 years) had abused methamphetamine.

The company reported that Nexafed is currently being sold in more than 2,600 U.S. pharmacies and has become the standard of care in many of these pharmacies. Repeat orders from pharmacies have also increased.

As on Aug 2013, Nexafed was distributed in about 1,400 U.S. pharmacies, of which about 66.7% were repeat customers. During the quarter and six months ended Jun 30, 2013, Acura shipped approximately $25,000 and $58,000 worth of Nexafed, respectively.

We are encouraged by the expansion in the distribution network of Nexafed. Nexafed is Acura’s second product to enter the market. Acura has initiated research on Impede 2.0, the next generation IMPEDE Technology, to upgrade Nexafed.

Acura has produced pilot scale quantities of Nexafed with IMPEDE 2.0 technology for further meth-resistance testing and pharmacokinetic testing. After successful testing, Acura will commercially introduce Nexafed using IMPEDE 2.0 technology.

Acura currently carries a Zacks Rank #3 (Hold). Other companies that look well-positioned include Questcor Pharmaceuticals Inc. , Actelion Ltd. (ALIOF) and Actavis, Inc. (ACT - Analyst Report). While Questcor is a Zacks Rank #1 (Strong Buy) stock, Actavis and Actelion are Zacks Rank #2 (Buy) stocks.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UNITED THER… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%
STRATTEC SE… STRT 80.24 +3.00%